Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TherapeuticsMD, Inc. (TXMD)
Price$2.22Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M | $20.1M | $15.0M | $8.8M | $3.8M | $2.1M | — |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M | $14.1M | $15.2M | $15.6M | $11.4M | $6.8M | $2.5M | $1.1M | — |
| Gross margin | — | — | 100.00% | 98.00% | 45.51% | 75.37% | 87.24% | 83.00% | 84.28% | 78.38% | 77.63% | 75.56% | 77.67% | 64.69% | 54.64% | — |
| Research & development | — | — | — | $0 | $7.1M | $10.4M | $19.8M | $27.3M | $33.9M | $53.9M | $72.0M | $43.2M | $13.6M | $4.5M | $107,241 | — |
| Operating expenses | $7.4M | $7.9M | $9.8M | $67.4M | $80.7M | $204.4M | $194.5M | $143.6M | $91.8M | $105.4M | $100.8M | $65.4M | $32.6M | $18.6M | $6.6M | — |
| Operating income | −$4.4M | −$6.1M | −$8.5M | $1.2M | −$79.6M | −$155.5M | −$151.2M | −$130.2M | −$77.6M | −$90.3M | −$85.2M | −$54.0M | −$25.8M | −$16.1M | −$5.4M | — |
| Operating margin | −145.27% | −347.08% | −654.61% | 1.70% | −3,092.77% | −239.77% | −304.56% | −808.85% | −462.69% | −466.27% | −422.93% | −359.65% | −294.09% | −422.95% | −259.90% | — |
| EBITDA | −$4.0M | −$5.6M | −$7.6M | $2.4M | −$78.8M | −$151.5M | −$149.8M | −$129.9M | −$77.4M | −$90.1M | −$85.1M | −$54.0M | −$25.8M | −$16.1M | −$5.4M | — |
| EBITDA margin | −132.56% | −318.17% | −583.79% | 3.41% | −3,064.17% | −233.50% | −301.76% | −807.02% | −461.42% | −465.59% | −422.62% | −359.30% | −293.43% | −421.48% | −257.28% | — |
| Net income | −$569,000 | −$2.2M | −$10.3M | $112.0M | −$172.4M | −$183.5M | −$176.1M | −$132.6M | −$76.9M | −$89.9M | −$85.1M | −$54.2M | −$28.4M | −$35.1M | −$12.9M | −$2.9M |
| Net profit margin | −18.83% | −123.85% | −789.40% | 160.08% | −6,700.93% | −282.90% | −354.79% | −823.74% | −458.50% | −464.32% | −422.37% | −360.82% | −323.84% | −919.86% | −618.40% | — |
| Basic EPSper basic share | -$0.05 | -$0.19 | -$0.99 | $12.41 | -$21.66 | -$33.50 | -$36.00 | -$29.50 | -$18.50 | -$23.00 | -$24.50 | -$18.00 | -$11.00 | -$19.00 | -$10.50 | — |
| Diluted EPSper diluted share | -$0.05 | -$0.19 | -$0.99 | $11.96 | -$21.66 | -$33.50 | -$36.00 | -$29.50 | -$18.50 | -$23.00 | -$24.50 | -$18.00 | -$11.00 | -$19.00 | -$10.50 | — |
Owners
Reported shareholders
10.30%of listed shares
Rubric Capital Management LP1.19M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Rubric Capital Management LP | 10.30%1.19M shares |
Clearline Capital LP | 5.49%635.22K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.06%353.7K shares |
Tejara Capital Ltd | 2.98%344.48K shares |
ADAR1 Capital Management, LLC | 2.96%342.45K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.27%146.6K shares |
MORGAN STANLEY | 1.12%129.22K shares |
BlackRock, Inc. | 0.99%115.15K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.91%105.85K shares |
CITADEL ADVISORS LLC | 0.74%86.1K shares |
Walker Marlan D | ≈0.64%73.64K shares |
VANGUARD FIDUCIARY TRUST CO | 0.55%63.83K shares |
Collins Cooper C. | ≈0.52%60.52K shares |
Thompson Tommy G | ≈0.32%37.51K shares |
STATE STREET CORP | 0.26%30.1K shares |
XTX Topco Ltd | 0.18%21.25K shares |
DIMENSIONAL FUND ADVISORS LP | 0.17%19.72K shares |
NORTHERN TRUST CORP | 0.16%18.56K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.15%17K shares |
OSAIC HOLDINGS, INC. | 0.13%15.2K shares |
Percentages use 11.57M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 23, 2025Form 4 | Thompson Tommy GDirector | BuyCommon Stock | 8.4K | $1.67 | $14.0K | 23.2K |
| Apr 14, 2025Form 4 | Thompson Tommy GDirector | BuyCommon Stock | 325 | $1.00 | $325.00 | 14.8K |
| Apr 14, 2025Form 4 | Walker Marlan DChief Executive Officer | BuyCommon Stock | 490 | $1.00 | $490.00 | 73.6K |
| Apr 10, 2025Form 4 | Walker Marlan DChief Executive Officer | BuyCommon Stock | 1.2K | $0.86 | $1.0K | 73.1K |
| Apr 9, 2025Form 4 | Walker Marlan DChief Executive Officer | BuyCommon Stock | 1.1K | $0.87 | $988.32 | 72.0K |